 Multiple Myeloma
"Multiple Myeloma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.
| Descriptor ID |
D009101
|
| MeSH Number(s) |
C04.557.595.500 C14.907.454.460 C15.378.147.780.650 C15.378.463.515.460 C20.683.515.845 C20.683.780.650
|
| Concept/Terms |
Multiple Myeloma- Multiple Myeloma
- Multiple Myelomas
- Myeloma, Multiple
- Myelomas, Multiple
- Myeloma-Multiple
- Myeloma Multiple
- Myeloma-Multiples
- Plasma Cell Myeloma
- Cell Myeloma, Plasma
- Cell Myelomas, Plasma
- Myelomas, Plasma Cell
- Plasma Cell Myelomas
- Kahler Disease
- Disease, Kahler
- Myeloma, Plasma-Cell
- Myeloma, Plasma Cell
- Myelomas, Plasma-Cell
- Plasma-Cell Myeloma
- Plasma-Cell Myelomas
- Myelomatosis
- Myelomatoses
|
Below are MeSH descriptors whose meaning is more general than "Multiple Myeloma".
Below are MeSH descriptors whose meaning is more specific than "Multiple Myeloma".
This graph shows the total number of publications written about "Multiple Myeloma" by people in this website by year, and whether "Multiple Myeloma" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1981 | 0 | 4 | 4 | | 1982 | 0 | 1 | 1 | | 1983 | 1 | 1 | 2 | | 1986 | 0 | 1 | 1 | | 1987 | 0 | 2 | 2 | | 1989 | 2 | 0 | 2 | | 1991 | 0 | 1 | 1 | | 1992 | 1 | 1 | 2 | | 1993 | 1 | 0 | 1 | | 1995 | 1 | 0 | 1 | | 1996 | 0 | 1 | 1 | | 1997 | 1 | 0 | 1 | | 1998 | 2 | 1 | 3 | | 1999 | 1 | 1 | 2 | | 2000 | 1 | 2 | 3 | | 2001 | 2 | 0 | 2 | | 2002 | 3 | 0 | 3 | | 2003 | 0 | 1 | 1 | | 2004 | 3 | 0 | 3 | | 2005 | 2 | 2 | 4 | | 2006 | 3 | 1 | 4 | | 2007 | 3 | 1 | 4 | | 2008 | 4 | 0 | 4 | | 2009 | 5 | 3 | 8 | | 2010 | 4 | 4 | 8 | | 2011 | 10 | 2 | 12 | | 2012 | 13 | 0 | 13 | | 2013 | 7 | 0 | 7 | | 2014 | 11 | 2 | 13 | | 2015 | 10 | 0 | 10 | | 2016 | 11 | 0 | 11 | | 2017 | 18 | 2 | 20 | | 2018 | 10 | 1 | 11 | | 2019 | 14 | 0 | 14 | | 2020 | 16 | 0 | 16 |
To return to the timeline, click here.
Below are the most recent publications written about "Multiple Myeloma" by people in Profiles.
-
Landgren O, Siegel D, Kazandjian D, Costa L, Jakubowiak A. Treatments for newly diagnosed multiple myeloma: when endurance is interrupted. Lancet Oncol. 2020 12; 21(12):e540.
-
Jasielec JK, Kubicki T, Raje N, Vij R, Reece D, Berdeja J, Derman BA, Rosenbaum CA, Richardson P, Gurbuxani S, Major S, Wolfe B, Stefka AT, Stephens L, Tinari KM, Hycner T, Rojek AE, Dytfeld D, Griffith KA, Zimmerman TM, Jakubowiak AJ. Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma. Blood. 2020 11 26; 136(22):2513-2523.
-
Zhou H, Lei M, Wang W, Guo M, Wang J, Zhang H, Qiao L, Feng H, Liu Z, Chen L, Hou J, Wang X, Gu C, Zhao B, Izumchenko E, Yang Y, Zhu Y. In vitro and in vivo efficacy of the novel oral proteasome inhibitor NNU546 in multiple myeloma. Aging (Albany NY). 2020 11 16; 12(22):22949-22974.
-
Voorhees PM, Kaufman JL, Laubach J, Sborov DW, Reeves B, Rodriguez C, Chari A, Silbermann R, Costa LJ, Anderson LD, Nathwani N, Shah N, Efebera YA, Holstein SA, Costello C, Jakubowiak A, Wildes TM, Orlowski RZ, Shain KH, Cowan AJ, Murphy S, Lutska Y, Pei H, Ukropec J, Vermeulen J, de Boer C, Hoehn D, Lin TS, Richardson PG. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2020 08 20; 136(8):936-945.
-
Costa LJ, Derman BA, Bal S, Sidana S, Chhabra S, Silbermann R, Ye JC, Cook G, Cornell RF, Holstein SA, Shi Q, Omel J, Callander NS, Chng WJ, Hungria V, Maiolino A, Stadtmauer E, Giralt S, Pasquini M, Jakubowiak AJ, Morgan GJ, Krishnan A, Jackson GH, Mohty M, Mateos MV, Dimopoulos MA, Facon T, Spencer A, Miguel JS, Hari P, Usmani SZ, Manier S, McCarthy P, Kumar S, Gay F, Paiva B. International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials. Leukemia. 2021 01; 35(1):18-30.
-
Derman BA, Jasielec J, Langerman SS, Zhang W, Jakubowiak AJ, Chiu BC. Racial differences in treatment and outcomes in multiple myeloma: a multiple myeloma research foundation analysis. Blood Cancer J. 2020 08 07; 10(8):80.
-
Derman BA, Jasielec JK, Jakubowiak AJ. Clinician attitudes and practices toward measurable residual disease in multiple myeloma. Br J Haematol. 2020 08; 190(3):470-472.
-
Nabulsi NA, Alobaidi A, Talon B, Asfaw AA, Zhou J, Sharp LK, Sweiss K, Patel PR, Ko NY, Chiu BC, Calip GS. Self-reported health and survival in older patients diagnosed with multiple myeloma. Cancer Causes Control. 2020 Jul; 31(7):641-650.
-
Chari A, Vogl DT, Jagannath S, Jasielec J, Unger TJ, DeCastro A, Shah J, Kauffman M, Shacham S, Jakubowiak A. Selinexor-based regimens for the treatment of myeloma refractory to chimeric antigen receptor T cell therapy. Br J Haematol. 2020 05; 189(4):e126-e130.
-
Gavriatopoulou M, Chari A, Chen C, Bahlis N, Vogl DT, Jakubowiak A, Dingli D, Cornell RF, Hofmeister CC, Siegel D, Berdeja JG, Reece D, White D, Lentzsch S, Gasparetto C, Huff CA, Jagannath S, Baz R, Nooka AK, Richter J, Abonour R, Parker TL, Yee AJ, Moreau P, Lonial S, Tuchman S, Weisel KC, Mohty M, Choquet S, Unger TJ, Li K, Chai Y, Li L, Shah J, Shacham S, Kauffman MG, Dimopoulos MA. Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials. Leukemia. 2020 09; 34(9):2430-2440.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|